A metanalysis of pregnancy outcomes in women with psoriasis and psoriatic arthritis finds an excess risk of adverse maternal events, but not adverse neonatal events.
This systematic review included 16 studies meeting inclusion criteria.
Search for Terms or Answers
A metanalysis of pregnancy outcomes in women with psoriasis and psoriatic arthritis finds an excess risk of adverse maternal events, but not adverse neonatal events.
This systematic review included 16 studies meeting inclusion criteria.
Bimekizumab (BIM) is a monoclonal antibody that targets both interleukin-17A and interleukin-17F, which as a biologic target has worked well in the management of psoriatic disease. The current issue of the NEJM has two reports wherein BIM was shown to be more effective than secukinumab and adalimumab in treating patients with moderate-to-severe plaque psoriasis; however, safety concerns arise.
Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.
Analysis of patients receiving anti–tumor necrosis factor α (TNFi) therapy in the British Society for Rheumatology Biologics Register (BSRBR) shows that the risk of demyelination is rare but is marginally increased by taking TNFi therapy.
The lung and its pathology is uniquely tied to rheumatoid arthritis (RA) and its pathogenesis. A new study shows that elevation of anti–citrullinated protein antibodies (ACPAs) before diagnosis of RA increases the risk of developing chronic obstructive pulmonary disease (COPD
Herpes zoster reactivation -- a.k.a. shingles -- following COVID-19 vaccination in six patients with comorbid autoimmune/inflammatory diseases may be a new adverse event associated with the Pfizer/BioNTech mRNA vaccine, suggested a new report.
Broadalumab (Siliq), an anti-interleukin-17 receptor A monoclonal antibody, is currently FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axial spondyloarthritis (axSpA).
Dr. Jack Cush serves up this week's news and articles from RheumNow.com.
Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found.
Analysis of ongoing safety from the secukinumab (SEC) drug development program shows a low risk for malignancy in SEC patients treated for up to five years for either psoriasis, psoriatic arthritis (PsA) or ankylosing spondylitis (AS).
A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do.
Treatment with denosumab (Prolia) helped heal bone erosions over 2 years among patients with rheumatoid arthritis whose disease activity was well controlled, researchers reported.
A survey study from the ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.
No drug is FDA approved to manage the skin or joint complaints of systemic sclerosis (SSc); a recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients.
Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.